A New Drug For The Treatment Of Obesity Entered The U.S. Market
Food and Drug Administration (FDA) has allowed the use of hypoglycemic agent liraglutide as anti-obesity drug. Developed by Novo Nordisk, it will be marketed under the trade name Saksenda.
Liraglutide can be used for the treatment of obese adults with at least one weight-related disease (type 2 diabetes, high blood pressure or high cholesterol).
The drug was approved by the FDA for the treatment of type 2 diabetes in 2010.As an antidiabeticmedication liraglutide is sold under the trade name Viktoza. It is worth noting that Saksenda contains a higher dose of liraglutide than Viktoza does.
Studies have shown that liraglutide (3 mg daily) helps patients lose at least 5% of their weight in 50% cases, while 22% of the patients achieve 10% percent weight loss .
- Reduce Weight Not Following A Strict Diet
- Persimmons: Help In Weight Loss
- How Not To Gain Weight On Holidays